Papua New GuineaTuberculosis profile
Population  2014 7.5 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3 (1.9–4.3) 40 (25–58)
Mortality (HIV+TB only) 0.54 (0.33–0.8) 7.2 (4.4–11)
Prevalence  (includes HIV+TB) 39 (19–68) 529 (251–908)
Incidence  (includes HIV+TB) 31 (23–41) 417 (304–547)
Incidence (HIV+TB only) 3.5 (2.4–4.8) 47 (32–64)
         
Case detection, all forms (%) 84 (64–120)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.7 (1.1–4.3) 19 (8.5–30)
MDR-TB cases among notified pulmonary
TB cases
390 (160–630) 500 (220–780)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 840   208
Pulmonary, clinically diagnosed 10 716    
Extrapulmonary 11 406   0
       
Total new and relapse 26 170    
Previously treated, excluding relapses 2 397    
Total cases notified 28 567    
Among 25 962 new cases:
6 959 (27%) cases aged under 15 years;
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB     2 162
Laboratory-confirmed RR-/MDR-TB cases     320
Patients started on MDR-TB treatment ***     320
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 218 (25)
HIV-positive TB patients 781 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 246 (31)
HIV-positive TB patients on antiretroviral therapy (ART) 484 (62)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (67) 3 617
Previously treated cases registered in 2013 (57) 587
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (55) 85
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 20
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 24
% Funded domestically 53%
% Funded internationally 47%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-09 Data: www.who.int/tb/data